YP01001

YP01001 is an orally bioavailable, small molecule multi-target tyrosine kinase inhibitor (TKI) developed by Chongqing Yaoyou Pharmaceutical, a subsidiary of Fosun Pharma. It is designed to inhibit several key pathways involved in tumor angiogenesis and cell proliferation, specifically targeting the Vascular Endothelial Growth Factor Receptor (VEGFR) and the RET proto-oncogene. The drug is primarily being investigated for the treatment of advanced solid tumors, with a particular clinical focus on medullary thyroid cancer and other thyroid malignancies. By blocking these signaling pathways, YP01001 aims to disrupt the blood supply to tumors and inhibit the growth of cancer cells that are driven by RET mutations or over-expression.